Medication risk in portfolio assessment
Identify and assess medication risk factors in underwriting portfolios and incorporate medication governance into pricing and risk management
Published: 3 April 2026 | Updated: 3 April 2026
Medication as a portfolio risk factor
As an underwriter, you assess portfolio risk across multiple dimensions: claim frequency, injury severity, occupational hazards, claimant demographics. Medication management is often overlooked in portfolio assessment, yet it significantly influences portfolio risk and claims outcomes. A portfolio with poor medication governance experiences longer claim durations, higher medication costs, more complications, and worse return-to-work outcomes than identical portfolios with strong medication management.
Medication risk is assessable, manageable, and predictable. Unlike some risk factors beyond your control, medication governance is directly influenced by insurer policies, case management practices, and clinical engagement. Understanding medication risk and incorporating it into your underwriting approach improves portfolio pricing accuracy and loss ratios.
Key insight: Portfolios with proactive medication governance show 15-25% better loss ratios on average compared to portfolios without medication management programs. This difference is measurable and directly attributable to medication governance.
Medication risk dimensions in portfolio assessment
Medication cost exposure
Portfolio medication costs vary significantly based on:
- Injury mix: Portfolios with higher proportions of musculoskeletal injuries typically have higher opioid and pain medication costs
- Severity distribution: Higher proportions of severe injuries drive greater medication complexity and costs
- Claimant demographics: Older workers and workers with pre-existing conditions take more medications on average
- Medication governance: Portfolios without deprescribing focus accumulate higher medication costs over claim duration
- Provider prescribing patterns: Portfolios with high-prescribing providers experience higher medication costs
Average portfolio medication costs as percentage of total claim spend range from 10-30% depending on mix. Understanding your specific portfolio baseline is essential for accurate risk assessment.
Claim duration and closure risk
Poor medication management extends claim duration. Medications create barriers to functional recovery, workplace return, and claim closure. Portfolios with medication mismanagement experience:
- Extended average claim duration by 12-36 months
- Higher long-tail claim prevalence
- Reduced return-to-work rates
- Lower closure success rates when approached
Complication rates
Inappropriate medications create medication-related complications. Falls from sedating medications, GI bleeds from NSAIDs, withdrawal issues from dependence medications, addiction concerns from opioids all create additional medical costs and extended recovery timelines. Portfolios with poor medication governance have higher complication rates and associated costs.
Return-to-work outcomes
Medication is a significant determinant of return-to-work success. Workers on appropriate medications return to work faster and more reliably. Portfolios with medication focus show higher return-to-work rates and faster return timelines. This translates to lower ongoing claim costs.
Regulatory and liability risk
Poor medication governance increases liability exposure. Medication-related adverse events can trigger complaints, regulatory scrutiny, or litigation. Portfolios with documented medication governance demonstrate duty of care and reduce liability exposure.
Assessing medication risk in your portfolio
Data collection for medication assessment
To assess medication risk, you need baseline data on your portfolio:
| Metric | How to Obtain | Interpretation |
|---|---|---|
| Average pharmacy spend per claim | Finance reporting; claims management system | Higher spend may indicate medication escalation or polypharmacy without governance |
| Percentage of claims on 5+ medications | Medication audit from medical records sampling | High prevalence indicates medication complexity and potential governance gap |
| Average claim duration by medication profile | Claims analysis stratified by medication count or class | Claims with polypharmacy should close faster if well-managed; if slower, governance gap exists |
| Return-to-work rates by medication status | RTW analysis stratified by whether medications are being optimised | Claims with medication review should have better RTW rates |
| Medication-related complication rates | Medical record review for falls, withdrawals, adverse events | Higher complication rates indicate risk that medication governance could reduce |
| Deprescribing prevalence | Claims audit for documented medication reduction plans | Low prevalence indicates medication governance gap; medications may continue unnecessarily |
Benchmarking your medication risk
Once you have baseline metrics, benchmark against expectations:
- Benchmark portfolio medication cost: 15-25% of total claim spend is typical. Higher suggests governance gap.
- Benchmark polypharmacy prevalence: 15-20% of claims on 5+ medications is typical for mixed portfolios. Higher suggests escalation without governance.
- Benchmark deprescribing: 30-50% of claims with documented medication reduction planning is realistic. Lower suggests medication reduction is not standard practice.
- Benchmark medication-related complications: 5-10% of claims experience medication-related adverse events. Higher suggests medication selection or monitoring issues.
Medication governance as an underwriting consideration
Medication governance practices should inform your underwriting decisions:
Portfolio pricing adjustments
Portfolios with strong medication governance should receive pricing consideration recognising lower medication-driven costs and better outcomes. Conversely, portfolios without medication governance warrant pricing uplift reflecting expected medication cost escalation and extended claim duration.
Risk conditions in underwriting
Consider requiring or incentivising medication governance in underwriting conditions:
- Mandatory medication review for claims over certain cost thresholds
- Deprescribing requirements for medications with dependence liability
- Regular medication monitoring for complex claims
- Specialist pharmacy engagement for polypharmacy cases
Claims management service specifications
When engaging claims management services, specify medication governance expectations:
- Regular medication assessment in claims monitoring
- Specialist medication review for identified high-risk cases
- Documented medication reduction plans for medications with closure implications
- Monitoring of deprescribing implementation and outcomes
Medication risk indicators for high-risk claims
| Medication Risk Indicator | Risk Level | Underwriting Action |
|---|---|---|
| Six or more regular medications | High | Require medication review; mandatory deprescribing goal |
| Benzodiazepines beyond 12 weeks | High | Require cessation plan; monitor for dependence and withdrawal issues |
| High-dose or long-duration opioids | High | Require specialist pain management input; pain medication reduction planning |
| Medication costs exceeding 20% of total monthly claim spend | High | Mandate medication review to identify cost reduction opportunities |
| Medication escalation despite plateau in functional recovery | High | Review medication appropriateness; consider alternative interventions |
| Claim duration exceeding expected timeline with no deprescribing plan | High | Initiate medication governance; develop closure-focused deprescribing strategy |
| Medication-related adverse event or reported side effect | Moderate-high | Request medical review; assess medication appropriateness |
| Sedating medications limiting work or rehabilitation capacity | Moderate | Plan medication adjustment to support functional recovery |
Building medication governance into underwriting policy
Medication review triggers
Establish clear triggers for mandatory medication review in your underwriting policy:
- All claims in specified high-risk categories (severe injury, high-cost, long-duration)
- Claims developing polypharmacy (5+ medications)
- Claims with medication cost escalation
- Claims with identified medication side effects limiting recovery
- Claims approaching long-tail classification (beyond 24-36 months)
Medication governance standards
Establish your expectations for medication management in claims:
- Regular medication review frequency (e.g., quarterly for high-risk claims)
- Mandatory deprescribing planning for medications with dependence liability
- Cost monitoring and action thresholds
- Documentation standards for medication decisions
- Specialist engagement requirements (when pharmacy review is mandatory)
Performance metrics
Measure medication governance effectiveness in your portfolio:
- Percentage of high-risk claims receiving medication review
- Medication cost changes following intervention
- Claim duration changes for claims with medication management versus without
- Return-to-work rates for claims with medication optimisation
- Medication-related complication rates
Communicating medication governance expectations to claims managers
To claims managers: "Medication management is now a key performance metric in our claims management process. We expect you to assess medication appropriateness in all moderate and severe claims. For claims with polypharmacy or cost escalation, we require specialist medication review. Your KPIs include medication cost management and deprescribing rate. Here are the resources and budget to support this expectation."
To providers: "We are implementing systematic medication governance in our claims. We may refer claims for specialist medication review to assess appropriateness and identify optimization opportunities. We value your clinical input on medication decisions and want to ensure we are providing evidence-based, cost-effective medication management that supports claimant recovery."
ROI of medication governance in portfolio underwriting
What does medication governance cost your portfolio, and what return does it generate?
Portfolio-level ROI calculation example
Portfolio: 2,000 active claims
Medication governance program cost:
- Specialist medication reviews: 300 claims at $900 each = $270,000
- Program management and coordination = $50,000
- Training and process implementation = $25,000
- Total annual cost = $345,000
Medication governance benefits:
- Reduced medication costs: $400 average per reviewed claim = $120,000
- Claim acceleration: 3-month average closure acceleration on 200 claims = $750,000 (assuming $150k average claim value)
- Improved RTW: 15% improvement in RTW rate on 300 reviewed claims reduces long-tail exposure = $200,000
- Total benefit = $1,070,000
Net ROI = (1,070,000 - 345,000) / 345,000 = 2.1x return
Medication governance programs typically generate 2-5x return on investment in portfolio context. The program cost is quickly offset by reduced medication costs, claim acceleration, and improved outcomes.
Competitive advantage through medication governance
In the insurance market, medication governance is a differentiator. Insurers with mature medication governance capabilities can:
- Price portfolios more accurately by accounting for medication-driven cost factors
- Offer more competitive pricing on portfolios with strong medication governance potential
- Deliver better outcomes, supporting customer satisfaction and retention
- Reduce liability exposure and risk profile
- Position themselves as specialists in evidence-based claims management
Integrating medication governance into underwriting processes
Make medication governance a standard underwriting and risk management function:
- Include medication assessment in portfolio risk analysis for all accounts
- Establish medication governance expectations in underwriting conditions
- Monitor medication governance metrics in account performance reporting
- Build specialist medication expertise into your claims teams or engage external specialists
- Invest in training for claims staff on medication risk factors
- Establish medication governance as a standard service offering for accounts
Ready to assess and manage medication risk in your portfolio?
IMM's medication governance services help underwriters assess medication risk, implement medication management programs, and measure outcomes. Request a consultation to discuss medication governance strategy for your portfolio.
Request a Medication Review
